Treat-to-Target in RA Hits the Bull’s-eye

Solomon and colleagues from multiple centers looked at rates of adverse events, office visits, and diagnostic utilization before, during, and after implantation of the treat-to-target (TTT) initiative for rheumatoid arthritis (RA) and found no significant difference before or after.¹ Thumb through the slides for the details of their study and the take-home points for clinicians.